The End for (Another) Hepatitis C Drug Candidate

The Tufts Center for the Study of Drug Development estimates that only one out of every five drugs that go to phase 1 clinical trials is ever approved by the Food and Drug Administration. On Wednesday, ViroPharma (Nasdaq: VPHM  ) and Wyeth (NYSE: WYE  ) announced that HCV-796 joined the long list of compounds that have failed in clinical testing.

HCV-796 was the two companies' antiviral non-nucleoside polymerase inhibitor that was intended to treat hepatitis C. Last year, the partners reported mixed phase 2 results for the drug: The HCV-796 combination therapy produced solid benefits for patients, compared with using only the currently approved hepatitis C standards of care. The problem was that the drug also elevated some patients' liver enzyme levels (which could indicate future liver problems if not corrected), so ViroPharma and Wyeth decided to halt continued dosing of the drug but continued to track patients in the study.

Apparently, ViroPharma and Wyeth weren't impressed enough to go forward with HCV-796, deciding to cancel any more testing and shut down their hepatitis C collaboration. Along with changes in a patient's QT interval (a portion of heart rhythm), raised liver enzymes are a top reason why many drugs fail in clinical testing.

The story of HCV-796 and other antiviral compounds like Idenix's (Nasdaq: IDIX  ) valopicitabine or Boehringer Ingelheim's protease inhibitor should serve as a reminder of the risks involved in drug development and the safety issues that many antiviral hepatitis C compounds in development have experienced.

It's easy to forget that a drug that is shown to be effective can still be a clinical or commercial failure if there are other, adverse effects. This is something that all investors and analysts (like myself) should keep in mind when getting excited about some of the blowout short-term data seen in other hepatitis C antiviral compounds like InterMune's (Nasdaq: ITMN  ) ITMN-191 or Pharmasset's (Nasdaq: VRUS  ) R7128.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 624039, ~/Articles/ArticleHandler.aspx, 10/27/2016 1:17:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,211.87 12.54 0.07%
S&P 500 2,137.92 -1.51 -0.07%
NASD 5,231.61 -18.66 -0.36%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
VPHM.DL $0.00 Down +0.00 +0.00%
ViroPharma CAPS Rating: ***
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***
IDIX.DL $0.00 Down +0.00 +0.00%
Idenix Pharmaceuti… CAPS Rating: **
ITMN.DL $0.00 Down +0.00 +0.00%
InterMune CAPS Rating: **